Recent News for CANF - Can-Fite Biopharma Ltd Sponsored ADR (Israel)

Date Title
Apr 5 Can-Fite Says Cannabinoid-Based Therapies Stop Liver Cancer Growth, Preclinical Studies Show
Apr 5 TSLA, NVTA, CHPT and NNOX among premarket gainers
Apr 5 Can-Fite cannabis compound inhibits liver cancer growth
Apr 5 Can-Fite: Cannabis Compound Inhibits Liver Cancer Growth in Preclinical Studies
Mar 30 Can-Fite existing out-licensing deals reports $130M potential milestone payments remaining
Mar 30 Can-Fite: Summary of Existing Out-licensing Deals with Potential Milestone Payments of up to approximately $130 million
Mar 25 Can-Fite Biopharma EPS beats by $1.22, misses on revenue
Mar 25 Can-Fite Reports 2020 Financial Results & Provides Clinical Development Update
Mar 19 Can-Fite BioPharma Interview to Air on Bloomberg Television U.S. on the RedChip Money Report®
Mar 18 HEXO, CSIQ, LAZR and SIG among premarket gainers
Mar 18 Can-Fite: Topical Administration of CF602 Fully Recovers Erectile Dysfunction in Diabetic Model
Mar 16 Mid-Afternoon Market Update: Crude Oil Down 1%; SunLink Health Systems Shares Spike Higher
Mar 16 Why Can-Fite, Moderna, AC Immune Shares Are Rallying
Mar 16 Mid-Morning Market Update: Markets Mixed; Jabil Beats Q2 Views
Mar 16 5 Top Stock Gainers for Tuesday: Moderna, Can-Fite BioPharma
Mar 16 The Daily Biotech Pulse: Fulgent Nabs CDC Contract, Enzo Rallies, Solid Biosciences Releases Gene Therapy Data, Moderna Begins Pediatric Vaccine Study
Mar 16 Can-Fite BioPharma Surges on $42.7 Million Deal With Ewopharma
Mar 16 Can-Fite shares surge 75% on out-licensing psoriasis, liver disease drug rights
Mar 16 Can-Fite Signs $42.7 Million Out-Licensing Deal with Ewopharma
Mar 5 Enrollment underway in Can-Fite Bio's mid-stage COVID-19 study
Mar 5 Can-Fite Enrolls First Patient in Phase II COVID-19 Study Under FDA Protocol
Feb 26 Pacira's (PCRX) Q4 Earnings Top Estimates, Revenues Miss
Feb 22 Can-Fite BioPharma's Namodenoson Improves Liver Function, Long Term Data Shows
Feb 22 Can-Fite (CANF) shares soar 45% on positive namodenoson data in liver cancer
Feb 22 New Positive Data from Can-Fite’s Liver Cancer Phase II Clinical Study with Namodenoson
Back to the Main CANF Page...